Alfacell And GENESIS Pharma SA Announce Exclusive Licensing Agreement For ONCONASE In Southeast Europe

BLOOMFIELD, N.J. and ATHENS, Greece--(BUSINESS WIRE)--Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease therapeutics for cancer, today announced that it has entered into a exclusive licensing and distribution agreement with GENESIS Pharma S.A., for the commercialization of ONCONASE® (ranpirnase), the Company’s lead drug candidate. ONCONASE is currently being evaluated in a confirmatory Phase IIIb clinical trial in unresectable malignant mesothelioma (UMM).